• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Monday

    1/9/23 11:20:01 AM ET
    $ARVN
    $CERS
    $CIO
    $CUTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    EDP Services
    Technology
    Get the next $ARVN alert in real time by email

    Companies That Fell Through 52-Week Lows Monday

    During Monday's morning trading, 14 companies set new 52-week lows.

    Things to Consider About Today's 52-Week Lows:

    • L3Harris Technologies (NYSE:LHX) was the biggest company on a market cap basis to set a new 52-week low.
    • The smallest company by market cap to hit a new 52-week low was Nabriva Therapeutics (NASDAQ:NBRV).
    • Cutera (NASDAQ:CUTR) shares traded down 23.86% to reach its 52-week low, making it the biggest loser.
    • Nabriva Therapeutics (NASDAQ:NBRV)'s stock made the biggest reversal, trading up 0.77% shortly after dropping to a new 52-week low.

    Here is a list of stocks that set new 52-week lows on Monday:

    • L3Harris Technologies (NYSE:LHX) stock hit a new 52-week low of $200.33. The stock was down 1.31% on the session.
    • Arvinas (NASDAQ:ARVN) stock dropped to a yearly low on Monday of $27.00. Shares traded down 12.8%.
    • Cutera (NASDAQ:CUTR) shares hit a yearly low of $29.49. The stock was down 23.86% on the session.
    • Cerus (NASDAQ:CERS) shares set a new 52-week low of $3.06. The stock traded down 17.99%.
    • PMV Pharma (NASDAQ:PMVP) shares hit a yearly low of $8.08. The stock was down 3.23% on the session.
    • City Office REIT (NYSE:CIO) stock set a new 52-week low of $8.03 on Monday, moving down 1.72%.
    • PIMCO California (NYSE:PCQ) shares reached a new 52-week low of $12.20 on Monday morning, moving down 1.48%.
    • DLH Hldgs (NASDAQ:DLHC) stock hit a new 52-week low of $10.80. The stock was down 9.24% on the session.
    • Peak Bio (NASDAQ:PKBO) shares set a new yearly low of $2.84 this morning. The stock was down 11.93% on the session.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $ARVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARVN
    $CERS
    $CIO
    $CUTR

    CompanyDatePrice TargetRatingAnalyst
    Arvinas Inc.
    $ARVN
    1/6/2026$15.00Neutral → Buy
    Citigroup
    L3Harris Technologies Inc.
    $LHX
    12/16/2025$367.00Equal-Weight → Overweight
    Morgan Stanley
    L3Harris Technologies Inc.
    $LHX
    12/12/2025$331.00Buy
    Citigroup
    L3Harris Technologies Inc.
    $LHX
    11/18/2025$290.00Neutral
    BNP Paribas Exane
    Arvinas Inc.
    $ARVN
    10/15/2025$6.00Neutral → Sell
    Goldman
    Arvinas Inc.
    $ARVN
    9/24/2025$10.00Buy → Neutral
    BofA Securities
    Arvinas Inc.
    $ARVN
    9/17/2025$16.00Overweight
    Barclays
    Arvinas Inc.
    $ARVN
    6/2/2025$9.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $ARVN
    $CERS
    $CIO
    $CUTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    L3Harris to Present at Upcoming Investor Conference

    L3Harris Technologies (NYSE:LHX) will present at the J.P. Morgan Industrials Conference in Washington at 12:55 p.m. ET on Wednesday, March 18. Missile Solutions President Ken Bedingfield will deliver the presentation, which will stream live on L3Harris.com. A recording will also become available following the event. About L3Harris Technologies L3Harris is the Trusted Disruptor in defense tech. With customers' mission-critical needs always in mind, our employees deliver end-to-end technology solutions connecting the space, air, land, sea and cyber domains in the interest of national security. Visit L3Harris.com for more information. View source version on businesswire.com: https://www

    3/13/26 10:00:00 AM ET
    $LHX
    Industrial Machinery/Components
    Industrials

    L3Harris Appoints Sam Mehta President, Space & Mission Systems and Communications & Spectrum Dominance Segments

    L3Harris Technologies (NYSE:LHX) today announced an update to the leadership structure supporting its three reportable business segments, reinforcing the company's continued focus on execution, operational performance, and customer mission. Effective immediately, Sam Mehta has been appointed President overseeing both the Space & Mission Systems and Communications & Spectrum Dominance segments. The company expects to continue reporting financial results for each of its three segments separately, consistent with its previously announced structure. Mehta and Ken Bedingfield, who leads the Missile Solutions segment, will continue to report directly to Chairman and Chief Executive Officer Chri

    3/12/26 8:30:00 AM ET
    $LHX
    Industrial Machinery/Components
    Industrials

    Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

    – Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson's disease – NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson's disease (PD) will be presented at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026), March 17-21, 2026, in Copenhagen, Denmark. ARV-102 is Arvinas' investigational, orally bio

    3/11/26 7:00:00 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $CERS
    $CIO
    $CUTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Arvinas upgraded by Citigroup with a new price target

    Citigroup upgraded Arvinas from Neutral to Buy and set a new price target of $15.00

    1/6/26 8:21:48 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    L3Harris upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded L3Harris from Equal-Weight to Overweight and set a new price target of $367.00

    12/16/25 8:39:52 AM ET
    $LHX
    Industrial Machinery/Components
    Industrials

    Citigroup initiated coverage on L3Harris with a new price target

    Citigroup initiated coverage of L3Harris with a rating of Buy and set a new price target of $331.00

    12/12/25 8:51:27 AM ET
    $LHX
    Industrial Machinery/Components
    Industrials

    $ARVN
    $CERS
    $CIO
    $CUTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Morrison Briggs bought $268,070 worth of shares (20,000 units at $13.40), increasing direct ownership by 26% to 96,021 units (SEC Form 4)

    4 - ARVINAS, INC. (0001655759) (Issuer)

    3/9/26 4:05:21 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Mink Brook Asset Management Llc bought $44,264 worth of shares (8,048 units at $5.50) (SEC Form 4)

    4 - DLH Holdings Corp. (0000785557) (Issuer)

    2/20/26 4:31:07 PM ET
    $DLHC
    Professional Services
    Consumer Discretionary

    Large owner Mink Brook Asset Management Llc bought $135,844 worth of shares (24,699 units at $5.50) (SEC Form 4)

    4 - DLH Holdings Corp. (0000785557) (Issuer)

    2/18/26 5:23:56 PM ET
    $DLHC
    Professional Services
    Consumer Discretionary

    $ARVN
    $CERS
    $CIO
    $CUTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: President and CEO Teel Randy was granted 147,179 shares, increasing direct ownership by 98% to 296,875 units (SEC Form 4)

    4/A - ARVINAS, INC. (0001655759) (Issuer)

    3/12/26 5:40:35 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Chief Medical Officer Benjamin Richard J was granted 55,220 shares and sold $250,932 worth of shares (125,894 units at $1.99), decreasing direct ownership by 7% to 879,101 units (SEC Form 4)

    4/A - CERUS CORP (0001020214) (Issuer)

    3/10/26 7:05:49 AM ET
    $CERS
    EDP Services
    Technology

    Chief Financial Officer Green Kevin Dennis was granted 63,854 shares and sold $169,646 worth of shares (83,021 units at $2.04), decreasing direct ownership by 2% to 1,168,095 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    3/9/26 9:56:38 PM ET
    $CERS
    EDP Services
    Technology

    $ARVN
    $CERS
    $CIO
    $CUTR
    SEC Filings

    View All

    SEC Form N-CEN filed by PIMCO California Municipal Income Fund

    N-CEN - PIMCO CALIFORNIA MUNICIPAL INCOME FUND (0001140411) (Filer)

    3/13/26 3:34:42 PM ET
    $PCQ
    Investment Managers
    Finance

    L3Harris Technologies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - L3HARRIS TECHNOLOGIES, INC. /DE/ (0000202058) (Filer)

    3/12/26 8:32:27 AM ET
    $LHX
    Industrial Machinery/Components
    Industrials

    SEC Form S-8 filed by PMV Pharmaceuticals Inc.

    S-8 - PMV Pharmaceuticals, Inc. (0001699382) (Filer)

    3/6/26 9:23:25 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $CERS
    $CIO
    $CUTR
    Leadership Updates

    Live Leadership Updates

    View All

    L3Harris Appoints Sam Mehta President, Space & Mission Systems and Communications & Spectrum Dominance Segments

    L3Harris Technologies (NYSE:LHX) today announced an update to the leadership structure supporting its three reportable business segments, reinforcing the company's continued focus on execution, operational performance, and customer mission. Effective immediately, Sam Mehta has been appointed President overseeing both the Space & Mission Systems and Communications & Spectrum Dominance segments. The company expects to continue reporting financial results for each of its three segments separately, consistent with its previously announced structure. Mehta and Ken Bedingfield, who leads the Missile Solutions segment, will continue to report directly to Chairman and Chief Executive Officer Chri

    3/12/26 8:30:00 AM ET
    $LHX
    Industrial Machinery/Components
    Industrials

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Oksenholt Capital Slams City Office REIT's "Lowball" Elliott Capital Offer, Calls for New Leadership and Strategic Restructuring

      Oksenholt Capital Management LLC ("Oksenholt Capital") today announced that its Chief Executive Officer, Jon Oksenholt, has sent a formal letter to the Chairman of the Board of City Office REIT, Inc. (NYSE:CIO), outlining serious concerns about the company's leadership, performance, and opposition to the proposed merger with affiliates of Elliott Capital. The letter identified several issues related to City Office REIT, Inc.'s ("CIO") current management and voiced opposition to the pending proposed acquisition/merger with affiliates of Elliott Capital. Affiliates of Oksenholt Capital Management LLC have Acquired Several Hundred Thousand Shares of City Office REIT, Inc., Comprising

    10/7/25 6:00:00 PM ET
    $CIO
    Real Estate Investment Trusts
    Real Estate

    $ARVN
    $CERS
    $CIO
    $CUTR
    Financials

    Live finance-specific insights

    View All

    Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

    2025 Total Revenue of $233.8 million, up 16% from 2024; 2025 Product Revenue of $206.1 million, up 14% from 2024 Strengthened Financial Foundation Through Strong Commercial Execution and Disciplined Operational Management Cerus Corporation (NASDAQ:CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. "Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world's blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components," said William "Obi" Greenman, Cerus' pres

    3/2/26 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    – Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – – ARV-102 (LRRK2) Phase 1 clinical data in patients with Parkinson's disease accepted for oral presentation at AP/PD Conference in March 2026 – – Clinical data from ARV-806 (KRAS G12D) and ARV-393 (BCL6) on track for presentations in 2026 – – Phase 1 trial in healthy volunteers initiated with polyQ-AR degrader ARV-027; first immuno-oncology PROTAC HPK1 degrader, ARV-6723, on track to initiate Phase 1 trial in mid-2026 – – Randy Teel, Ph.D., appointed President, Chief Executive Officer, and

    2/24/26 7:00:00 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026

    Cerus Corporation (NASDAQ:CERS) announced today its fourth quarter and full-year 2025 financial results will be released on Monday, March 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay will

    2/17/26 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    $ARVN
    $CERS
    $CIO
    $CUTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PMV Pharmaceuticals Inc.

    SC 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    12/12/24 12:29:41 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by City Office REIT Inc.

    SC 13G/A - City Office REIT, Inc. (0001593222) (Subject)

    11/14/24 4:05:11 PM ET
    $CIO
    Real Estate Investment Trusts
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

    SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

    11/14/24 1:22:38 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care